

1-18. (CANCELED)

19. (CURRENTLY AMENDED) A solution to be administered to a patient for at least one of diagnosis and treatment of tissue or a cell lesion by localized irradiation using a beam emitted by a source of light energy, comprising:

a physiologically acceptable solvent; and

~~the solution comprising~~ an ester of 5-aminolevulinic acid (E-ALA) for generating protoporphyrin IX (PpIX);

~~wherein a concentration of the ester of 5-aminolevulinic acid (E-ALA) in the solution is~~ which is present in the solution at a concentration of less than 1% by weight.

20. (PREVIOUSLY ADDED) The solution according to claim 19, wherein the concentration of ester of 5-aminolevulinic acid (E-ALA) in the solution ranges between 0.01% by weight to 0.5% by weight.

21. (PREVIOUSLY ADDED) The solution according to claim 19, wherein the ester of 5-aminolevulinic acid (E-ALA) is a hexylester of 5-aminolevulinic acid (h-ALA).

22. (CURRENTLY AMENDED) The solution according to claim 19, wherein ~~the solution is produced by dissolving~~ the ester of 5-aminolevulinic acid (E-ALA) is dissolved in a solvent which is compatible with a human organism.

23. (PREVIOUSLY ADDED) The solution according to claim 22, wherein the solvent is selected from the group consisting of sterilized water, physiological NaCl solution, a phosphate buffer solution and alcohol.

24. (CURRENTLY AMENDED) The solution according to claim 22, wherein ~~a PH of the solution contains is adjusted by a component to adjust the pH of the solution~~ to a physiological value ranging from about 4.8 to about 8.1.

25. (PREVIOUSLY ADDED) The solution according to claim 19, wherein the solution comprises a complementary substance for preventing transformation of the protoporphyrin IX (PpIX) into a heme by iron complexing in the cells.

26. (CURRENTLY AMENDED) The solution according to claim 25, wherein the complementary substance is ~~an~~ diaminoethyl tetra acetate (EDTA).

27. (PREVIOUSLY ADDED) The solution according to claim 25, wherein the complementary substance is deferroxamine.

28. (PREVIOUSLY ADDED) The solution according to claim 25, wherein the complementary substance is desferal.

29. ~~-(CURRENTLY AMENDED)~~ The solution according to claim 19, wherein the ~~solution is produced by dissolving the ester of 5-aminolevulinic acid (E-ALA)~~ is dissolved in a solvent which is compatible with an animal organism.

30. (PREVIOUSLY ADDED) The solution according to claim 29, wherein the solvent is selected from the group consisting of sterilized water, physiological NaCl solution, a phosphate buffer solution and alcohol.

31. (CURRENTLY AMENDED) The solution according to claim 29, wherein ~~a PH of the solution contains is adjusted by a component to adjust the pH of the solution~~ to a physiological value ranging from about 4.8 to about 8.1.

32. (PREVIOUSLY ADDED) The solution according to claim 19, wherein, following administering the Solution to the patient and irradiation of the tissue or the cell lesion by the source of light energy, a fluorescence emitted by protoporphyrin IX (PpIX) generated by the ester of 5-aminolevulinic acid (E-ALA) contained in the solution is detected to facilitate diagnoses of the tissue or the cell lesion.

33. (CURRENTLY AMENDED) A solution to be administered to a patient for at least one of diagnosis and treatment of tissue or a cell lesion by localized irradiation using a beam emitted by a source of light energy, the solution comprising:

a physiologically acceptable solvent;

an ester of 5-aminolevulinic acid (E-ALA) for generating protoporphyrin IX (PpIX) which is dissolved in the solvent at a concentration of less than 1% by weight;

~~wherein a concentration of the ester of 5-aminolevulinic acid (E-ALA) in the solution is less than 1% by weight, which is produced by dissolving the ester of 5-aminolevulinic acid (E-ALA) in a solvent which is compatible with a living organism;~~

a PH of the solution pH in the range of ranges from about 4.8 to about 8.1;

and

~~the solution has~~ a complementary substance for preventing transformation of protoporphyrin IX (PpIX) into a heme by iron complexing in live cells, ~~and the complementary substance is selected from the group comprising an~~ diaminoethyl tetra acetate (EDTA), deferroxamine and desferal.

34. (PREVIOUSLY ADDED) The solution according to claim 33, wherein the concentration of ester of 5-aminolevulinic acid (E-ALA) in the solution ranges between 0.01% by weight to 0.5% by weight.

09/673,871

35. (PREVIOUSLY ADDED) The solution according to claim 34, wherein, following administering the solution to the patient and irradiation of the tissue or the cell lesion by the source of light energy, a fluorescence emitted by protoporphyrin IX (PpIX) generated by the ester of 5-aminolevulinic acid (E-ALA) contained in the solution is detected to facilitate diagnoses of the tissue or the cell lesion.